Core Viewpoint - The company has reported its 2025 semi-annual results, highlighting key financial metrics and strategic initiatives, including share repurchase plans and stock incentive programs, while maintaining compliance with regulatory requirements [1][17][31]. Company Overview - The company, Ningbo Tianyi Medical Instruments Co., Ltd., has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4]. - The company plans to repurchase shares using its own funds, with a total repurchase amount between RMB 30 million and RMB 60 million, targeting a maximum price of RMB 50.00 per share [3][5]. Financial Data and Indicators - The company completed a share repurchase of 1,427,400 shares, representing 2.42% of its total share capital, with a total transaction amount of approximately RMB 57.64 million [5]. - The company has approved a stock incentive plan to grant 2.343 million restricted stocks to eligible employees, with a grant price of RMB 22.11 per share [6][7]. Important Events - The company has engaged in a joint investment with an affiliate to acquire CRRT business assets for EUR 43.54 million, with the transaction completed in February 2025 [9][10]. - The company is in the process of establishing an overseas production base in Thailand, reallocating funds from a previously planned project to support this initiative [11][12]. Fundraising and Usage - The company raised a total of RMB 771.77 million from its public offering, with a net amount of RMB 694.56 million after deducting fees [43]. - As of June 30, 2025, the company has nine dedicated fundraising accounts and has utilized RMB 60 million for cash management, including structured deposits and large certificates of deposit [44][45]. Compliance and Reporting - The board and supervisory committee have unanimously approved the semi-annual report and the special report on the use of raised funds, confirming compliance with relevant regulations [22][35].